Sign in

CIK 0001907108 · <br>Emerging growth company

Lexeo Therapeutics, Inc.

Sign in to watch
Ticker
LXEO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
854012572
Phone
(212) 547-9879
Business address
345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010
  1. 4 Derivatives Options or other derivatives
  2. 3 Insider Initial Statement of Ownership
  3. 4 Planned sale Chief Executive Officer sold 55,000 shares at $5.69 ($313,137)
  4. 4 Grant or award Chief Executive Officer acquired 2,623 shares (grant or award)
  5. 4 Grant or award Chief Operating Officer acquired 5,930 shares (grant or award)
  6. 4 Open-market sale Chief Operating Officer sold 3,016 shares at $6.40 ($19,294)
  7. 4 Open-market sale Chief Executive Officer sold 10,173 shares at $6.38 ($64,924)
  8. 4/A Open-market sale Chief Operating Officer sold 721 shares at $9.27 ($6,684)
  9. 4 Grant or award Chief Medical Officer acquired 49,500 shares (grant or award)
  10. 4 Grant or award Chief Executive Officer acquired 161,665 shares (grant or award)
  11. 4 Grant or award Chief Operating Officer acquired 65,000 shares (grant or award)
  12. 4 Grant or award Chief Financial Officer acquired 44,665 shares (grant or award)
  13. 3 Insider Initial Statement of Ownership
  14. 4 Open-market sale Chief Executive Officer sold 1,127 shares at $9.27 ($10,447)
  15. 4 Open-market sale Chief Medical Officer sold 615 shares at $9.27 ($5,701)
  16. 4 Open-market sale Chief Development Officer sold 386 shares at $9.27 ($3,578)
  17. 4 Open-market sale Chief Legal Officer sold 549 shares at $9.27 ($5,089)
  18. 4 Open-market sale Chief Technical Officer sold 721 shares at $9.27 ($6,684)
  19. 4 Open-market sale Chief Development Officer sold 3,888 shares at an average $8.94 ($34,767)
  20. 4 Open-market sale Chief Legal Officer sold 3,526 shares at an average $8.94 ($31,530)

Page 2 of 7 · 121 filings